Rational design of a DNA-launched live attenuated vaccine against human enterovirus 71

Human Enterovirus 71 (EV71) has emerged as one of the predominant causative agents of hand, foot and mouth disease (HFMD) with global impact. Despite the inactivated vaccine being licensed, other vaccine candidates based on advanced technology platforms are under development. In this report, we rationally designed and constructed two DNA-launched live attenuated vaccine candidates (pDL-EV71) under the control of specific promoters. In vitro and in vivo transfection with pDL-EV71 driven by the CMV promoter successfully yielded fully infectious EV71. More importantly, the administration of pDL-EV71 did not cause clinical symptoms following intracranial or intramuscular inoculation in neonatal and IFNα/βR−/− mice, demonstrating its safety profile. Moreover, a single-dose or two-dose immunization with pDL-EV71 elicited robust neutralizing antibodies against EV71 as well as an antigen-specific cellular response in mice. A single-dose immunization with 10 ​μg of pDL-EV71 conferred complete protection against lethal EV71 infection in neonates born to immunized maternal mice. Overall, our present results demonstrate that pDL-EV71 is a safe and effective vaccine candidate against EV71 for further development. •We developed a DNA-launched live attenuated vaccine candidate (pDL-EV71) against EV71 infection.•Fully infectious EV71 were successfully recovered following in vitro and in vivo transfection with pDL-EV71.•A single dose immunization with pDL-EV71 induces neutralizing antibodies and antigen-specific cellular responses in mice.•A single dose immunization with pDL-EV71 confers complete protection against lethal EV71 infection in neonatal mice.